Pacira BioSciences Shares Surge 44% on Viatris Acquisition Report
Pacira BioSciences stock rose 44.03% to about $36.30 on October 8, 2026, after a report said Viatris would acquire the company for $36.50 per share in cash. The proposed deal was valued at $1.65 billion and expected to close by the end of 2026. Technical readings on the daily, hourly, and 15-minute charts were overbought.
Pacira BioSciences, ticker PCRX, jumped 44.03% on Oct. 8, 2026, trading near $36.30 versus a prior close of $25.20. A pre-open report said Viatris would buy the company for $36.50 a share in cash, a proposed $1.65 billion deal expected to finish by year-end 2026. Earlier, Pacira reportedly partnered with Italy’s Molteni Farmaceutici for European distribution of EXPAREL.
Technical gauges were stretched: daily RSI14 was 84.98, hourly 90.74, and 15-minute 94.38. The stock sat above its 20-, 50-, and 200-session EMAs, while the daily MACD remained positive.
If completed, the proposed acquisition could affect Pacira shareholders through a fixed cash payout, while employees, suppliers, and clinicians may face integration uncertainty. Patients using EXPAREL might see continuity or changes in availability and pricing as a larger owner and European distribution partner take shape. Investors in Viatris may weigh the deal’s cost and strategic fit. Broader market watchers may view the premium as a signal of continued consolidation in specialty pharmaceuticals, though regulatory and closing risks could alter the outcome.